Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Malvern, Pennsylvania Tuesday, July 22, 2025, 17:00 Hrs [IST] ...

As per Election Commission of India 12,817 new polling stations have been added in the state to prevent long queues at the ...

Election Commission of India ensures electoral roll accuracy in Bihar through Special Intensive Revision, involving political ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today provides an update on its commercial and operational ...

It's been over a month since Khaby Lame, the most followed TikToker ever, was detained by ICE, and one MAGA supporter just can't stop bragging about it.

SC was hearing petitions raising concerns over the Special Intensive Revision exercise being undertaken in the poll-bound state & the 11-document list being accepted by ECI.

ImmunityBio sees bullish momentum from ASCO data and UK approval for ANKTIVA, despite FDA and cash risks. Check out why IBRX ...

India’s quiet support for Tibetan culture has provided refuge and continuity for the Dalai Lama’s teachings, making Himalayan ...